Latest Press Releases
Adaptive CEO joins distinguished panel at Genomics 2.0 Conference to Discuss Company’s Pipeline of Cancer Diagnostics
Adaptive announced today that Chad Robins, its Founder and Chief Executive Officer, is participating in a panel discussion this morning at the prestigious Genomics 2.0 Conference in Park City, Utah. The panel, entitled “Changing the Game in Oncology,” includes other industry notables Randy Scott, CEO of Invitae, Steven Kafka, COO of Foundation Medicine, and Ronnie Andrews, Division President at Thermo Fisher.
Veteran Microsoft Executive and Distinguished Engineer, Sean Nolan, joins Adaptive Biotechnologies as Chief Technology Officer
Adaptive is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company’s expanding Executive Leadership Team. Mr. Nolan’s hire, the second management hire this month, represents Adaptive’s continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.
Study Reports clonoSEQ Detects Residual Disease in 33% More Childhood Leukemia Patients Compared to Current Standard of Care Laboratory Test
Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling
Veteran Genomic Health Executive, Dean Schorno, CPA, joins Adaptive Biotechnologies as Chief Financial Officer
Adaptive is pleased to announce the appointment of Dean Schorno, CPA,. as Chief Financial Officer and the newest member of the Company’s expanding Executive Leadership Team.
Adaptive Biotechnologies and Collaborators to Present Data Advancing the Clinical Utility of Immunosequencing at the 50th Annual Meeting of the American Society of Clinical Oncology
Adaptive and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology.
Adaptive Biotechnologies CEO Highlights Company’s Work in Cancer Immunotherapy at the “What’s Hot in Cancer Immunotherapy” Event at the Fred Hutchinson Cancer Research Center
Adaptive Biotechnologies Corporation CEO, Chad Robins, highlights today the companies’ work in cancer immunotherapy at the “What’s Hot in Cancer Immunotherapy” event hosted by Xconomy at the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website
Adaptive Biotechnologies Announces Completion of Series C and Series D Financing Rounds Through a $105 million Private Investment from Viking Global Investors
Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
Adaptive CEO Chad Robins speaking today at “The Future of Healthcare in Washington” conference beginning at 1PM. His talk is titled “How Genomics is Enabling Diagnostics that will Change Clinical Practice.”